Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Teijin Pharma to Launch Ipsen’s Somatuline Subcutaneous Injection in Japan
Jan. 18, 2013
Teijin Pharma and Ipsen announced the launch of Somatuline 60/90/120 mg for subcutaneous injection in Japan for the treatment of acromegaly and pituitary gigantism (when response to surgical therapies is not satisfactory or surgical therapies are difficult to perform).
Copyright ©2019. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing